These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1761923)

  • 21. Progressing From Metformin to Sulfonylureas or Meglitinides.
    Grant JS; Graven LJ
    Workplace Health Saf; 2016 Sep; 64(9):433-9. PubMed ID: 27621259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
    Furukawa H; Ishida H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
    [No Abstract]   [Full Text] [Related]  

  • 23. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Mühlhauser I; Sawicki PT; Berger M
    Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
    [No Abstract]   [Full Text] [Related]  

  • 24. Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
    Raccah D
    Diabetologia; 2007 May; 50(5):1109-10; author reply 1111. PubMed ID: 17351766
    [No Abstract]   [Full Text] [Related]  

  • 25. Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
    Tayek JA
    Diabetologia; 2006 Nov; 49(11):2807-8. PubMed ID: 16955252
    [No Abstract]   [Full Text] [Related]  

  • 26. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfonylureas in the treatment of diabetes mellitus--1985.
    Gerich JE
    Mayo Clin Proc; 1985 Jul; 60(7):439-43. PubMed ID: 3925246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].
    Mukai E; Fujimoto S; Inagaki N
    Nihon Rinsho; 2011 May; 69(5):907-11. PubMed ID: 21595280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type II diabetes: role of first- and second-generation drugs.
    Washington SE; Mazzaferri EL
    Geriatrics; 1986 Nov; 41(11):51-6, 59-60, 64. PubMed ID: 3770483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
    Fadini GP; Saragoni S; Russo P; Degli Esposti L; Vigili de Kreutzenberg S; Melazzini M; Avogaro A;
    Diabetes Obes Metab; 2017 Oct; 19(10):1416-1424. PubMed ID: 28432754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
    Del Prato S; Pulizzi N
    Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
    Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with physicians' decision to discontinue or down-titrate sulfonylureas for type 2 diabetes patients.
    Laires P; Kurtyka K; Witt EA; Qiu Y; Yu S; Iglay K
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):71-79. PubMed ID: 30130985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
    Evans JM; Ogston SA; Emslie-Smith A; Morris AD
    Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) - a study protocol.
    Schrijnders D; de Bock GH; Houweling ST; van Hateren KJJ; Groenier KH; Johnson JA; Bilo HJG; Kleefstra N; Landman GWD
    BMC Cancer; 2017 Jun; 17(1):444. PubMed ID: 28645260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review.
    Chen Y; Du L; Li L; Ma J; Geng X; Yao X; Liu G; Sun X
    J Diabetes; 2017 May; 9(5):482-494. PubMed ID: 27273872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark.
    Pilemann-Lyberg S; Thorsteinsson B; Snorgaard O; Zander M; Vestergaard H; Røder ME
    Diabetes Res Clin Pract; 2015 Nov; 110(2):202-7. PubMed ID: 26515912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral hypoglycemic agents.
    Forbath N
    Prim Care; 1977 Dec; 4(4):629-36. PubMed ID: 337336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.